InspireMD, Inc. (NYSE:NSPR) Director Gary S. Roubin Acquires 41,322 Shares

Key Points

• InspireMD Director Gary S. Roubin purchased 41,322 shares at an average price of $2.42 per share, totaling nearly $100,000, increasing his stake in the company by 7.29%.
• The company's stock is currently trading at $2.69, experiencing a 3.6% decline in midday trading, with a market capitalization of $82.41 million.
• Recent institutional buying includes a 721.2% stake increase by Parkman Healthcare Partners LLC, reflecting growing institutional interest in InspireMD.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) Director Gary S. Roubin bought 41,322 shares of the company's stock in a transaction dated Wednesday, July 30th. The shares were acquired at an average cost of $2.42 per share, for a total transaction of $99,999.24. Following the completion of the transaction, the director owned 608,425 shares of the company's stock, valued at approximately $1,472,388.50. The trade was a 7.29% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

InspireMD Stock Down 2.6%

NSPR stock traded down $0.07 during midday trading on Tuesday, reaching $2.60. The company had a trading volume of 48,585 shares, compared to its average volume of 103,497. The stock has a 50 day moving average price of $2.43 and a 200 day moving average price of $2.61. InspireMD, Inc. has a fifty-two week low of $1.99 and a fifty-two week high of $3.80. The firm has a market capitalization of $79.65 million, a PE ratio of -3.47 and a beta of 0.60.

Hedge Funds Weigh In On InspireMD

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Parkman Healthcare Partners LLC lifted its position in InspireMD by 721.2% in the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock worth $2,248,000 after purchasing an additional 750,635 shares during the period. Nantahala Capital Management LLC increased its holdings in shares of InspireMD by 38.4% in the first quarter. Nantahala Capital Management LLC now owns 2,318,017 shares of the company's stock valued at $6,235,000 after buying an additional 643,452 shares in the last quarter. Huntleigh Advisors Inc. bought a new position in shares of InspireMD in the first quarter valued at $316,000. Courier Capital LLC acquired a new stake in InspireMD during the 1st quarter valued at $81,000. Finally, Northern Trust Corp raised its stake in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after purchasing an additional 24,452 shares during the period. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NSPR has been the subject of several research analyst reports. Piper Sandler lowered their price objective on InspireMD from $4.50 to $4.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Wall Street Zen initiated coverage on InspireMD in a report on Monday, May 5th. They issued a "sell" rating for the company.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.